C5a induces tissue factor activity on endothelial cells - PubMed (original) (raw)
Affiliations
- PMID: 9157602
C5a induces tissue factor activity on endothelial cells
K Ikeda et al. Thromb Haemost. 1997 Feb.
Abstract
Tissue factor (TF) is an integral membrane glycoprotein that serves as a cofactor for blood coagulation factor VIIa. The induction of TF on the surface of endothelial cells is initiated by various stimuli including lipopolysaccharide, interleukin-1 beta, and tumor necrosis factor alpha. We have demonstrated that recombinant human C5a induces TF activity in a dose-dependent fashion in human umbilical vein endothelial cells (HUVEC). Peak activity (4.9-fold increase) was obtained 3-6 h after treatment with 10 microM C5a. TF mRNA as assessed by RT-PCR method was also significantly increased (3.75-fold) after 3 h incubation with C5a, suggesting that C5a induces TF activity on HUVEC, at least in part, by enhancing the level of TF mRNA. The increase in TF activity by C5a was inhibited by methylprednisolone. The induction of TF on endothelial cells by C5a may represent one of many potential interrelationships between the inflammatory and coagulation schemes.
Similar articles
- [Expression of tissue factor induced by IL-6 in HUVEC].
Tang XL, Jiang ZY, Dong J, Liu XC, Cai SY, Xiao R, Lu YR. Tang XL, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Mar;37(2):234-7. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006. PMID: 16608083 Chinese. - Induction of tissue factor expression on human umbilical vein endothelial cells by cell-specific HLA class I antibody: preliminary data.
Naji A, Deschaseaux F, Racadot E, Ferrand C, Justrabo E, Guignier F, Mousson C, Rifle G. Naji A, et al. Transplant Proc. 2005 Jul-Aug;37(6):2892-3. doi: 10.1016/j.transproceed.2005.08.001. Transplant Proc. 2005. PMID: 16182846 - Tissue factor and the extrinsic pathway of coagulation during infection and vascular inflammation.
Carson SD, Johnson DR, Tracy SM. Carson SD, et al. Eur Heart J. 1993 Dec;14 Suppl K:98-104. Eur Heart J. 1993. PMID: 8131798 Review.
Cited by
- Immunity and Coagulation in COVID-19.
Avdonin PP, Blinova MS, Serkova AA, Komleva LA, Avdonin PV. Avdonin PP, et al. Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267. Int J Mol Sci. 2024. PMID: 39457048 Free PMC article. Review. - Effect of Unfractionated Heparin Dose on Complement Activation and Selected Extracellular Vesicle Populations during Extracorporeal Membrane Oxygenation.
Zipperle J, Vock L, Fritsch G, Grillari J, Osuchowski MF, Holnthoner W, Schöchl H, Halbgebauer R, Huber-Lang M, Hofmann N, Scharner V, Panigada M, Gratz J, Iapichino G. Zipperle J, et al. Int J Mol Sci. 2024 Oct 17;25(20):11166. doi: 10.3390/ijms252011166. Int J Mol Sci. 2024. PMID: 39456945 Free PMC article. Clinical Trial. - Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots.
Kang YH, Varghese PM, Aiyan AA, Pondman K, Kishore U, Sim RB. Kang YH, et al. Front Immunol. 2024 Jun 12;15:1368852. doi: 10.3389/fimmu.2024.1368852. eCollection 2024. Front Immunol. 2024. PMID: 38933264 Free PMC article. - Unraveling the Intricate Web: Complement Activation Shapes the Pathogenesis of Sepsis-Induced Coagulopathy.
Wei X, Tu Y, Bu S, Guo G, Wang H, Wang Z. Wei X, et al. J Innate Immun. 2024;16(1):337-353. doi: 10.1159/000539502. Epub 2024 May 31. J Innate Immun. 2024. PMID: 38815564 Free PMC article. Review. - The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.
Ma L, Willey J. Ma L, et al. Thromb Update. 2022 Aug;8:100117. doi: 10.1016/j.tru.2022.100117. Epub 2022 Jul 9. Thromb Update. 2022. PMID: 38620713 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous